Angeles Alvarez Secord

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study

  Gynecologic Oncology · 2026-06-12

• Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy

  International Journal of Gynecological Cancer · 2026-06-01

• Addressing barriers to FRα-directed therapy integration in platinum-resistant ovarian cancer: A multi-phase, community-informed initiative.

  Journal of Clinical Oncology · 2026-05-27

• Azenosertib plus paclitaxel for platinum-resistant ovarian cancer: Results from a phase 1b study.

  Journal of Clinical Oncology · 2026-05-27

• Associations between molecular classification and response to intra-uterine levonorgestrel device therapy in patients with medically managed endometrial cancer and endometrial intra-epithelial neoplasia: a multi-center Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium study

  International Journal of Gynecological Cancer · 2026-04-30

• Exploring the clinical application and outcomes of the FIGO 2023 endometrial cancer staging system in early-stage disease

  Gynecologic Oncology · 2026-04-23

• Mirvetuximab soravtansine plus carboplatin in folate receptor alpha-expressing recurrent platinum-sensitive ovarian cancer

  Gynecologic Oncology · 2026-04-23 · 1 citations

• Overall survival by histologic subtype within the molecular classification of endometrial cancer

  Gynecologic Oncology · 2026-04-23

• Cost and efficiency of universal versus selective next generation sequencing for advanced stage endometrial cancer

  Gynecologic Oncology · 2026-04-23

• Endometrial cancer: The patient voice is center stage

  Gynecologic Oncology · 2026-04-23

• Real-world outcomes of poly(ADP)-ribose polymerase inhibitor (PARPi) monotherapy (PARPi mono) vs PARPi + bevacizumab (PARPi+bev ) first-line maintenance (1LM) therapy in patients (pts) with homologous recombination-deficient (HRd) advanced ovarian cancer (aOC)

  Gynecologic Oncology · 2026-04-23

• AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy with atezolizumab (atezo) for patients (pts) with recurrent or persistent endometrial cancer (EC)

  Gynecologic Oncology · 2026-04-23

• POLE mutation analysis, molecular characterization, and associations with survival outcomes: Ancillary analysis of GOG-0258

  Gynecologic Oncology · 2026-04-23

• Cost and efficiency of universal versus selective next generation sequencing for advanced stage endometrial cancer

  Gynecologic Oncology · 2026-04-01

• Molecular Classification Refines Adjuvant Radiation Therapy Use in Stage III Endometrial Cancer Exhibiting No Specific Molecular Profile

  Practical Radiation Oncology · 2026-03-01

• Figure 2 from Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma

  2026-02-17

• Figure 4 from Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma

  2026-02-17

• Figure 3 from Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma

  2026-02-17

• Figure 5 from Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma

  2026-02-17

• Supplementary Data 1 from Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma

  2026-02-17